No FDA Compromise On Veregen Specifications In First Botanical NDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The first botanical NDA, MediGene’s Veregen (kunecatechins), illuminated gaps in the emerging regulatory framework for plant-derived prescription drugs, FDA review documents indicate.